<DOC>
	<DOCNO>NCT00720876</DOCNO>
	<brief_summary>RATIONALE : Vorinostat may stop growth cancer cell block enzymes need cell growth . Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Giving vorinostat together rituximab may kill cancer cell . PURPOSE : This phase II trial study side effect give vorinostat together rituximab see well work treat patient indolent non-Hodgkin lymphoma .</brief_summary>
	<brief_title>Vorinostat Rituximab Treating Patients With Indolent Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - To evaluate anti-tumor activity vorinostat rituximab , term objective response rate , time progression , survival , patient indolent non-Hodgkin lymphoma . - To assess toxicity profile regimen patient . OUTLINE : Patients receive oral vorinostat twice daily day 1-14 rituximab IV day 1 . Treatment repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Patients must histologically cytologically confirm indolent NonHodgkin 's Lymphoma ; include category newly diagnose relapsed/refractory follicular center lymphoma grade I , II , III , relapsed/refractory marginal zone Bcell lymphoma ( nodal extranodal ) , relapsed/refractory mantle cell lymphoma Patients must measurable disease compute tomography ( CT ) scan ; positron emission tomography ( PET ) scan evaluation desirable mandatory , patient negative PET scan measurable disease CT eligible Patients may four prior chemotherapeutic regimen ; steroid alone local radiation count regimen ( radiotherapy must complete least 14 day prior start vorinostat ) ; Rituxan alone count regimen ; however , Bexxar Zevalin ; treat patient , recent therapy must fail induce complete response ( i.e. , persistent disease CT PET ) , must disease progression recurrence recent therapy Patients may enrol relapse autologous stem cell transplant least three month transplant , allogeneic transplant least six month post transplant ; eligible either type transplant , patient active related infection ( i.e. , fungal viral ) ; case allogeneic transplant relapse , active acute graft versus host disease ( GvHD ) grade , chronic graft versus host disease mild skin , oral , ocular GvHD require systemic immunosuppression Life expectancy great 3 month Eastern Cooperative Oncology Group ( ECOG ) performance status 2 ( Karnofsky &gt; = 60 % ) Absolute neutrophil count &gt; = 1,000/mcL Platelets &gt; = 100,000/mcL Total bilirubin within normal institutional limit ; patient elevation unconjugated bilirubin alone , Gilbert 's disease , eligible Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamic pyruvic transaminase [ SGPT ] ) = &lt; 2.5 x institutional upper limit normal Creatinine include 2 mg/dl Premenopausal woman must negative serum pregnancy test prior entry study ; woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation ; woman become pregnant suspect pregnant participating study , inform treat physician immediately Ability understand willingness sign write informed consent document Patients chemotherapy within 4 week , radiotherapy within 2 week recover adverse event due agent administer 4 week earlier exclude ; include use steroid , may continue two day prior enrollment ; low dose chlorambucil stop two week prior begin vorinostat ; valproic acid stop least two week prior enrollment ; nitrosoureas mitomycin stop 6 week prior enrollment Patients may receive investigational agent Patients know brain metastasis exclude clinical trial unless metastasis control therapy treated steroid within past two month History allergic reaction attribute compound similar chemical biologic composition vorinostat There must plan patient receive concurrent hormonal , biological , radiation therapy Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant woman exclude study ; breastfeed discontinue mother treated vorinostat Human immunodeficiency virus ( HIV ) positive patient receive combination antiretroviral therapy ineligible ; addition , HIV patient receive combination antiretroviral therapy also ineligible Patients active malignancy ineligible study Patients preexist previous coagulation issue exclude study long 1 ) previous pulmonary embolism deep vein thrombosis adequately treat 2 ) actively receive Coumadin lovenox anticoagulation ; patient already coumadin lovenox need take additional 40 mg subcutaneous injection daily</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
</DOC>